Straits Times Index
3,301.78 +4.23 (+0.13%) S&P 500
5,484.78 +11.55 (+0.21%) Dow
38,924.44 +146.34 (+0.38%) Nasdaq
17,846.21 -10.81 (-0.06%) Bitcoin USD
64,752.51 -580.17 (-0.89%) CMC Crypto 200
1,348.26 -41.14 (-2.96%)
CRMD Dec 2024 3.000 call
- GlobeNewswire
CorMedix Inc. Receives FDA Feedback on Potential Label Expansion
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback to the Company’s request to discuss development plans for additional indications for DefenCath. The FDA provided supportive feedback regarding the Company’s plans to pursue an expanded ind
- GlobeNewswire
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B f
- GlobeNewswire
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath® (taurolidine and heparin). CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal D
